Buchumschlag

The NTCP-inhibitor Myrcludex B: effects on bile acid disposition and tenofovir pharmacokinetics

Myrcludex B acts as a hepatitis B and D virus entry inhibitor blocking the sodium taurocholate cotransporting polypeptide (SLC10A1). We investigated the effects of myrcludex B on plasma bile acid disposition, tenofovir pharmacokinetics, and perpetrator characteristics on cytochrome P450 (CYP) 3A. Tw...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Blank, Antje (VerfasserIn) , Eidam, Annette (VerfasserIn) , Hohmann, Nicolas (VerfasserIn) , Burhenne, Jürgen (VerfasserIn) , Meyer, Markus Robert (VerfasserIn) , Meier, Katrin (VerfasserIn) , Weiß, Johanna (VerfasserIn) , Bruckner, Thomas (VerfasserIn) , Urban, Stephan (VerfasserIn) , Mikus, Gerd (VerfasserIn) , Haefeli, Walter E. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2018
In: Clinical pharmacology & therapeutics
Year: 2018, Jahrgang: 103, Heft: 2, Pages: 341-348
ISSN:1532-6535
DOI:10.1002/cpt.744
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1002/cpt.744
Verlag, Volltext: https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.744
Volltext
Verfasserangaben:A Blank, A Eidam, M Haag, N Hohmann, J Burhenne, M Schwab, SFJ van de Graaf, MR Meyer, HH Maurer, K Meier, J Weiss, T Bruckner, A Alexandrov, S Urban, G Mikus and WE Haefeli
Beschreibung
Zusammenfassung:Myrcludex B acts as a hepatitis B and D virus entry inhibitor blocking the sodium taurocholate cotransporting polypeptide (SLC10A1). We investigated the effects of myrcludex B on plasma bile acid disposition, tenofovir pharmacokinetics, and perpetrator characteristics on cytochrome P450 (CYP) 3A. Twelve healthy volunteers received 300 mg tenofovir disoproxil fumarate orally and 10 mg subcutaneous myrcludex B. Myrcludex B increased total plasma bile acid exposure 19.2-fold without signs of cholestasis. The rise in conjugated bile acids was up to 124-fold (taurocholic acid). Coadministration of tenofovir with myrcludex B revealed no relevant changes in tenofovir pharmacokinetics. CYP3A activity slightly but significantly decreased by 29% during combination therapy. Myrcludex B caused an asymptomatic but distinct rise in plasma bile acid concentrations and had no relevant impact on tenofovir pharmacokinetics. Changes in CYP3A activity might be due to alterations in bile acid signaling. Long-term effects of elevated bile acids will require critical evaluation.
Beschreibung:Gesehen am 27.08.2018
Advance online publication 21 June 2017
Beschreibung:Online Resource
ISSN:1532-6535
DOI:10.1002/cpt.744

Ähnliche Einträge